Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer

Chinese Journal of Clinical Oncology

Volumn 35, Issue 16, 2008, Pages 905-907

  Li, Mingyi ^a   Huang, He ^b   Liang, Ying ^b   Tan, Jiemei ^a   Lin, Daren ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Breast cancer; Chemotherapy; Ovarian function; Zoladex

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GOSERELIN; HORMONE; PACLITAXEL;

ADULT; AGE DISTRIBUTION; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; FEMALE; FEMALE FERTILITY; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION; OVARY FUNCTION;

EID: 77951578148     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer [J]. J Clin Oncol, 1996, 14(5):1718-1729. (Pubitemid 26134232)
2. Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer [J]. Hum Reprod, 2006, 21(10):2583-2592.
3. Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young,early breast cancer patients[J]. Ann Oncol, 2006, 17(1):74-78. (Pubitemid 43033843)
4. Cockshott ID. Clinical pharmacokinetics of goserelin[J]. Clin Pharmacokinet, 2000, 39(1):27-48.
5. Jonat W, Kaufmann M, Sauerbrei W, et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study[J]. J Clin Oncol, 2002, 20(24): 4628-4635. (Pubitemid 36025278)
6. Kaufmann M, Jonat W, Blamey R, et al. Survial analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node- positive breast cancer[J]. Eur J Cancer, 2003, 39(12):1711-1717. (Pubitemid 36897608)
7. Recchia F, Sica G, De Filippis S, et al. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast can cer: a phase II pilot study[J]. Anticancer Drugs, 2002, 13(4): 417-424. (Pubitemid 34454728)
8. Matsumoto M, Miyauchi M, Yamamoto N, et al. Investigation of menstruation recovery after LH-RH agonist therapy for prememopausal patients with breast cancer[J]. Breast Cancer, 2000, 7(3):237-240.